Elite Pharmaceuticals (ELTP) Q1 2025 earnings summary

Executive summary

• Achieved $18.8 million in revenue for Q1 FY2025, a 109% increase year-over-year, driven by strong Elite label product sales and continuing a multi-year growth trend.

• Operating income rose to $3.9 million, up 141%–144% from the prior year quarter, reflecting robust performance from the Elite label.

• Net income was $0.6 million, down from $1.1 million, primarily due to a $2.8 million non-cash warrant derivative expense.

• Positive operating cash flow of $3.1 million, reversing a $2.7 million cash burn in the prior year quarter.

• Recent developments include FDA approval for generic Methotrexate Sodium and acquisition of three opioid ANDAs from Nostrum Laboratories.

Financial highlights

• Revenue for Q1 FY2025: $18.8 million, up from $8.9–$9.0 million in Q1 FY2024.

• Operating income: $3.9 million, up from $1.6 million year-over-year.

• Net income: $0.6 million, down from $1.1 million, impacted by a $2.8 million non-cash warrant revaluation.

• Cash as of June 30, 2024: $8.4–$8.8 million, up $1.3 million from March 31, 2024.

• Working capital increased to $29.1 million, up $2.2 million sequentially.

Outlook and guidance

• Expectation to achieve another record year in FY2025, continuing the multi-year growth trend.

• At least three new product launches anticipated within the next four months, with incremental revenue and profit increases expected over the next two to three quarters.

• Preparing to commercialize newly acquired ANDAs, though timing and revenue impact remain uncertain.

• Confident in ability to fund working capital needs for upcoming launches; additional financing available if required.